Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021
Esther Kissling
(1)
,
Mariëtte Hooiveld
(2)
,
Iván Martínez-Baz
(3, 4)
,
Clara Mazagatos
(5, 4)
,
Naoma William
(6)
,
Ana-Maria Vilcu
(7)
,
Marjolein Kooijman
(8)
,
Maja Ilić
(9)
,
Lisa Domegan
(10)
,
Ausenda Machado
(11)
,
Simon de Lusignan
(12)
,
Mihaela Lazar
(13)
,
Adam Meijer
(8)
,
Mia Brytting
(14)
,
Itziar Casado
(3, 4)
,
Amparo Larrauri
(4, 15)
,
Josephine-L Murray
(6)
,
Sylvie Behillil
(16, 17)
,
Brechje de Gier
(8)
,
Ivan Mlinarić
(9)
,
Joan O'Donnell
(10)
,
Ana Paula Rodrigues
(11)
,
Ruby Tsang
(12)
,
Olivia Timnea
(13)
,
Marit de Lange
(8)
,
Maximilian Riess
(14)
,
Jesús Castilla
(3, 4)
,
Francisco Pozo
(5)
,
Mark Hamilton
(6)
,
Alessandra Falchi
,
Mirjam Knol
(8)
,
Sanja Kurečić Filipović
(9)
,
Linda Dunford
(18)
,
Raquel Guiomar
(11)
,
Jade Cogdale
(19)
,
Carmen Cherciu
(13)
,
Tessa Jansen
(2)
,
Theresa Enkirch
(14)
,
Luca Basile
(4)
,
Jeff Connell
(18)
,
Verónica Gomez
(11)
,
Virginia Sandonis Martín
(5)
,
Sabrina Bacci
(20)
,
Angela Mc Rose
(1)
,
Lucia Pastore Celentano
(20)
,
Marta Valenciano
(1)
1
EpiConcept [Paris]
2 NIVEL - Netherlands Institute for Health Services Research [Utrecht]
3 IdiSNA - Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra
4 CIBERESP - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health
5 Institute of Health Carlos III
6 Public Health Scotland [Glasgow]
7 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
8 RIVM - National Institute for Public Health and the Environment [Bilthoven]
9 CIPH - Croatian Institute of Public Health [Zagreb]
10 HSE - Health Service Executive [Dublin]
11 INSA - Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal]
12 University of Oxford
13 Cantacuzino Institute [Romania]
14 Public Health Agency of Sweden
15 ISC - Instituto de Salud Carlos III [Madrid]
16 CNR - laboratoire coordonnateur - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]
17 CNRS-UMR3569 - Biologie des ARN et virus influenza - RNA Biology of Influenza Virus
18 UCD - University College Dublin [Dublin]
19 UKHSA - UK Health Security Agency [London]
20 ECDC - European Centre for Disease Prevention and Control [Stockholm, Sweden]
2 NIVEL - Netherlands Institute for Health Services Research [Utrecht]
3 IdiSNA - Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra
4 CIBERESP - Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health
5 Institute of Health Carlos III
6 Public Health Scotland [Glasgow]
7 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
8 RIVM - National Institute for Public Health and the Environment [Bilthoven]
9 CIPH - Croatian Institute of Public Health [Zagreb]
10 HSE - Health Service Executive [Dublin]
11 INSA - Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal]
12 University of Oxford
13 Cantacuzino Institute [Romania]
14 Public Health Agency of Sweden
15 ISC - Instituto de Salud Carlos III [Madrid]
16 CNR - laboratoire coordonnateur - Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris]
17 CNRS-UMR3569 - Biologie des ARN et virus influenza - RNA Biology of Influenza Virus
18 UCD - University College Dublin [Dublin]
19 UKHSA - UK Health Security Agency [London]
20 ECDC - European Centre for Disease Prevention and Control [Stockholm, Sweden]
Abstract
Introduction In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.